Robert L Coleman
Overview
Explore the profile of Robert L Coleman including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
454
Citations
15933
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Asare A, Previs R, Spinosa D, Fellman B, Scott A, Mulder I, et al.
Gynecol Oncol
. 2025 Feb;
194:112-118.
PMID: 39987772
Background: This study evaluated whether patients with epithelial ovarian, fallopian tube, and primary peritoneal carcinoma (OC) who are immediately re-treated with bevacizumab derive benefit after disease progression on a bevacizumab-containing...
2.
Koselke E, Kaspin-Powell L, Hough S, Howell J, Robert N, Neubauer M, et al.
J Adv Pract Oncol
. 2025 Jan;
1-10.
PMID: 39802530
Introduction: The Molecularly Informed Lung Cancer Treatment in a Community Cancer Network: A Pragmatic Consortium™ (MYLUNG) clinical trial platform aims to advance the use of precision medicine in patients with...
3.
Quesada S, Penault-Llorca F, Matias-Guiu X, Banerjee S, Barberis M, Coleman R, et al.
Eur J Cancer
. 2024 Dec;
215:115169.
PMID: 39693891
Background: Poly (ADP ribose) polymerase inhibitors (PARPis) are a treatment option for patients with advanced high-grade serous or endometrioid ovarian carcinoma (OC). Recent guidelines have clarified how homologous recombination deficiency...
4.
Mirza M, Lorusso D, Shen Q, Allonby O, Slim M, Borkowska K, et al.
Crit Rev Oncol Hematol
. 2024 Nov;
206:104555.
PMID: 39557140
Novel therapies are driving meaningful changes to the management of endometrial cancer (EC). Herein, a systematic literature review was conducted to evaluate the efficacy and safety of first-line treatments for...
5.
Coleman R, Perhanidis J, Kalilani L, Zimmerman N, Golembesky A, Moore K
Ther Adv Med Oncol
. 2024 Nov;
16:17588359241292272.
PMID: 39552638
Background: The NOVA study (NCT01847274) compared niraparib with placebo as a maintenance treatment for patients with recurrent ovarian cancer (OC) but was not powered to detect an overall survival (OS)...
6.
Coleman R, Lubinga S, Shen Q, Walder L, Burton M, Mathews C
Gynecol Oncol
. 2024 Nov;
192():24-31.
PMID: 39520771
Objective: Dostarlimab in combination with carboplatin-paclitaxel (CP) improves progression-free survival in patients with primary advanced or recurrent endometrial cancer (pA/rEC), including in patients whose cancer is mismatch repair-deficient (dMMR) or...
7.
Kim J, Kim S, Park E, Ha H, Kim J, Coleman R, et al.
Gynecol Oncol
. 2024 Nov;
179:24-32.
PMID: 39491079
Background: Current treatment strategies for primary epithelial ovarian cancer (EOC) have significantly evolved, and the value of complete cytoreduction has not yet been reassessed. The study aimed to investigate the...
8.
Moore K, Lorusso D, Oaknin A, Oza A, Colombo N, Van Gorp T, et al.
Gynecol Oncol
. 2024 Oct;
191:249-258.
PMID: 39461270
Objective: Mirvetuximab soravtansine-gynx (MIRV) is a novel antibody-drug conjugate targeting folate receptor alpha (FRα), which is overexpressed in epithelial ovarian cancer (EOC), with limited expression on normal tissues. This integrated...
9.
Grisham R, Monk B, Van Nieuwenhuysen E, Moore K, Fabbro M, OMalley D, et al.
Int J Gynecol Cancer
. 2024 Oct;
PMID: 39375168
Background: There are no approved treatments specifically for low grade serous ovarian cancer; current standard of care treatment options are limited in efficacy and tolerability. The combination of avutometinib with...
10.
Monk B, Coleman R, Tewari K, Randall L, Pothuri B, Slomovitz B, et al.
Gynecol Oncol
. 2024 Aug;
189:146-147.
PMID: 39142061
No abstract available.